trial · primary record
Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV
Influenza
| Phase | Phase 3 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 150 |
| Primary completion | 2026-06-26 |
| Primary endpoint | The seroconversion rates (SCRs) of hemagglutination inhibition (HI) antibodies against each antigen 28 days after vaccination. |
| Registry ID | NCT07211152 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:58:33.740Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07211152
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.